Merck (MRK) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Over the ...

Merck (NYSE: MRK) closed Tuesday's session down 0.87% at $128.26, breaking a six-session winning streak. The stock had gained 13.62% over the preceding six trading sessions, outperforming the S&P 500, ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced an agreement with the ADAP Crisis Task Force (ACTF) to help state AIDS Drug Assistance Programs (ADAPs) provide ...

Merck & Co., Inc. (NYSE: MRK) has had a fantastic six months, seeing its share price go up nearly 50%. The company has a valuable portfolio of assets that will enable strong shareholder returns, ...

As Merck looks for growth opportunities ahead of Keytruda’s tumble over the patent cliff, the company’s future now looks a bit brighter in the glow of two late-stage trial wins for cancer drug Welireg ...

A bipartisan group of United States lawmakers has opened national security investigations into whether five major ...

With potential passage of the BIOSECURE Act looming and WuXi Biologics seeing its share price and profits decline, the Chinese biopharma contract manufacturing giant is responding with a sizable ...

With pharma heavyweights clashing against one another and reeling in major sales in the ulcerative colitis (UC) | Merck is ...

Unlock your investing potential with TipRanks Premium - Now At 40% OFF! Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter The latest update is out from Merck & ...